(d) if so, what are the details thereof and what action has been taken thereon?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Findings and recommendtaions of the various committees are examined by the Officers of the Ministry.

(b) The findings of the Special Team and the Kelkar Committee were also examined by Officers in the Ministry.

(c) to (d) A number of anomalies in the report of the Kelkar Committee and complaints about suppressing of liabilities in the case of findings of Special Team were received. A Standing Committee was constituted to go into the anomalies in the recommendations of Kelkar Committee. It was also decided to separately the findings of the Special Team.

Production of essential drugs

887. SHRI SURESH PACHOURI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that the decontrol of prices and an increase in profitability of a large number of drugs under the 1986 policy led to increased production of essential drugs,

(b) if so, what are the comparative production figures;

(c) how much of the total production of drugs is consumed by the Government sector both Central and State; and

(d) whether the essential drugs in the country are still in shortage and the prices are so high that it is very difficult for a common man to purchase them?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Several essential and mand, de-licensing of drugs, availability increase in production in recent years due mass consumption drugs have registered to several reasons including increased de of technoolgy etc.

(b) Production of monitored drugs is published regularily in the annual Performance Budgets of this Ministry copies of which are available in the Parliament Library.

(c) This is not monitored by this Ministry.

(d) There is no shortage of drugs. The prices of essential drugs are controlled under DPCO.

Production of drugs needed for National Health Programme

888. SHRI SURESH PACHOURI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the comparative production figures of foreign companies both FERA and ex-FERA and Indian companies in the production of drugs required for National Health Programme;

(b) what percentage of drugs produced by the organised sector (in terms of sales turnover) is in the controlled category; and

(c) what are the names of the bulk drugs for which the Small Scale accounts for more than 25 per cent of the production?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Details of production of drugs used for National Health Pro

gramme in terms of three parameters *i.e.* in the enclosed.

Statement

Items	Production (MT)	
	Indian Companies	FERA/EX/FERA
Streptomycin	243.79	Nil
Tetracycline	81·87	102·46
Rifampicin	73·66	Nil
Sodium Sulphacetamide	48·09	Nil
Paracetamol	2·39	Nil
Hydrocortisone	Nil	11 Kgs.
PAS & Salts	45·37	29·11
INH	71·23	69·06
Thiacetazone	24·69	Nil
Ethambutol	407·99	Nil
Pyrazinamide	2·98	0·89
Chloroquine	110·43	30·73
Amodiaquine	8·88	11·28
DEC Citrate	Nil	17·17
Dapsone	5·6	17·95
Clofazimine	1·45 Kgs.	Nil

(b) and (c) These details are not monitored by this Ministry.

Manufacture of Ayurveda drugs in Kerala

889. SHRI B. K. HARIPRASAD: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Kerala Government is planning to manufacture five crore Rupees worth of Ayurveda drugs every year; if so, what are the details thereof;

(b) what will be the priority areas for selection of medicines as there is a tendency to manufacture non-essential medicines with high prices;

(c) whether large scale production of Ayurveda drugs will endanger medical plants reserves; if so, what corrective steps are proposed to be taken; and

(d) whether Government propose to establish similar units in other parts of the country?

THE MINISTER OF STATE OF THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI RASHEED MASOOD): (a) and to (d) Information is being collected and will be laid on the table of the Sabha.